Introduction
============

Gliomas are the most common among primary malignant brain tumors with the characteristic heterogeneity in histology, molecular profile and outcome. During the course of pathogenesis, brain tumors acquire malignancy features ranging from mild morphological signs of anaplasia in World Health Organization (WHO) grade I and II astrocytomas to highly malignant WHO grade III astrocytomas and especially grade IV astrocytomas, which also known as glioblastomas, with high mitotic activity, aberrant vasculature and necrosis. It is now known that glioblastomas can develop through two distinct pathways: 95% of glioblastomas are primary or *de novo* arising without clinically evident precursor, whereas secondary glioblastomas can progress in patients with previously histologically confirmed low grade gliomas. Both types of glioblastoma clinically manifest as an aggressive infiltrating brain tumor with patient survival less than 1 year [@B1]. From molecular standpoint, gliomas are highly heterogeneous brain tumors, which scholars have attempted to classify into clinically relevant subtypes according to gene expression and DNA methylation profiles [@B2], [@B3]. However, molecular markers that could routinely be used in clinical practice for determining malignancy grade of glioma with the high accuracy as well as to provide reliable diagnostic and prognostic information on this type of cancer are currently unknown.

Several molecular studies in meningiomas and gliomas have shown *NDRG2*(N-myc downstream regulated gene 2) gene as a promising diagnostic marker involved in brain tumor pathology [@B4]-[@B7]. The protein encoded by this gene, NDRG2, is a member of the non-enzymatic alpha/beta hydrolase superfamily [@B8]. NDRG2 is a cytoplasmic protein involved in cell differentiation, cell growth, neuronal plasticity, stress response and apoptosis [@B9]. Because of its high expression in brain tissue, *NDRG2* gene was related to some important functions and pathophysiological processes in the brain such as Alzheimer\'s disease, cerebral ischemia, etc. [@B10], [@B11]. The first evidence of *NDRG2* involvement in cancer was presented in glioblastomas, where *NDRG2* was shown to reduce tumor cell proliferation [@B12]. Subsequent studies demonstrated *NDRG2* as an inhibitor of extracellular matrix-based cancer cell invasion and migration in liver cancer cells [@B13]. In several cancer cell lines, *NDRG2* gene expression was shown to be hypoxia inducible and responsible for hypoxia-associated apoptosis, and also playing a role in hypoxia-induced radioresistance of cancer cells [@B14], [@B15]. A number of reports from studies on cancer tissues have shown that *NDRG2* expression was associated with differentiation and advanced grade of liver cancer, and esophageal squamous carcinoma [@B13], [@B16]. Reduced *NDRG2* expression was correlated with poor survival prognosis in patients with liver cancer, esophageal squamous cell carcinoma, colorectal cancer, clear cell renal cell carcinoma, gallbladder cancer, and lung cancer [@B13], [@B17]-[@B21].

With particular regard to glioma, recent clinical studies demonstrated *NDRG2* as a putative tumor suppressor gene silenced in the majority of glioblastomas [@B5], [@B7], [@B22]. However, the main mechanism that underlies NDRG2 silencing in glioma is unknown. There is also a debate whether *NDRG2* gene activity reflects on survival of glioma patient. Thus, the shortage of the consistent data on *NDRG2* involvement in gliomagenesis and conflicting evidence on association of *NDRG2* activity with glioma patient survival prompted us to investigate the role of epigenetic modification and expression of *NDRG2* gene in glioma progression and the resulting patient outcome by setting up a complex analysis of *NDRG2* activity at DNA, RNA and protein levels in gliomas of different malignancy grade. Understanding how *NDRG2* is involved in the process of gliomagenesis could help to understand more about the function and molecular regulatory mechanisms of this gene.

Material and methods
====================

Patients and tissue samples
---------------------------

We investigated 137 WHO grade I-IV gliomas: 14 (10.2%) pilocytic astrocytomas WHO grade I, 45 (32.8%) diffuse astrocytomas WHO grade II, 29 (21.2%) anaplastic astrocytomas grade III, and 49 (35.8%) malignant astrocytomas WHO grade IV (glioblastomas). All glioma tumors were surgically resected from patients without prior treatment and histologically diagnosed according to the 2007 WHO criteria [@B23] in the Department of Neurosurgery of Hospital of Lithuanian University of Health Sciences, Kaunas, Lithuania, from 2003 through 2012. Database closure was in September 2013. Investigation have been performed in accordance with the principles of Declaration of Helsinki and approved by the Ethics Committee for Biomedical Research of the Lithuanian University of Health Sciences. All patients gave written informed consent. The following clinical data were collected for each patient: age at the time of the operation, gender, time of the last follow-up and patient life status. Patient survival has been calculated from the date of operation to the date of analysis or death of the patient.

Methylation analyses were performed on all 137 samples, however, due to the scarcity of the material, NDRG2 expression studies were conducted with two smaller groups of samples. More specifically, 112 glioma samples (10 astrocytomas grade I, 39 astrocytomas grade II, 20 astrocytomas grade III and 43 glioblastomas) were used for mRNA studies, whereas 88 tumor samples (12 astrocytomas grade I, 31 astrocytomas grade II, 18 astrocytomas grade III and 27 glioblastomas) were used for Western blot analysis. Noteworthy, the overlap between these two sample groups was 77 glioma samples (9 astrocytomas grade I, 29 astrocytomas grade II, 13 astrocytomas grade III and 26 glioblastomas).

DNA extraction. MS-PCR
----------------------

Brain tumor tissue specimens after dissection were snap-frozen in liquid nitrogen and stored until analysis. Tumor DNA was purified from 50-100 mg of frozen tissue using ZR Genomic DNA Tissue MiniPrep (Zymo Research) according to manufacturer\'s protocol. Methylation status of *NDRG2* gene promoter was determined by bisulfite treatment of DNA. 400 ng of total genomic DNA was modified using EZ DNA Methylation Kit (Zymo Research). Bisulfite-treated DNA was eluted in 40 µl nuclease-free water, and stored in -80°C until analysis. \"Human brain DNA\" (Zymo Research, Catalog No. D5018) served as a normal brain tissue control. For negative methylation control normal human blood lymphocyte DNA treated with bisulfite was used. Bisulfite Converted Universal Methylated Human DNA Standard (Zymo Research) was used as a positive control for DNA methylation. Promoter methylation was detected by methylation-specific PCR (MSP). Each MSP reaction incorporated approximately 20 ng of bisulfite-treated DNA as template. Specific primers for methylated and unmethylated target DNA sequence were designed according to the published data [@B24]. MSP primers for methylated *NDRG2* allele were: 5\'-AGAGGTATTAGGATTTTGGGTACG-3\' (sense) and 5\'-GCTAAAAAAACGAAA ATCTCGC-3\' (antisense) and for unmethylated allele: 5\'-AGAGGTATTAGGATTTT GGGTATGA-3\' (sense) and 5\'-CCACTAAAAAAACAAAAATCTCACC-3\' (antisense). Reaction was performed in 15 µl of total volume by using 7.5 µl Maxima Hot Start PCR Master Mix (Thermofisher Scientific) with Hot start Taq DNA polymerase and 10 pmol of each primer (Metabion International AG). MSP was performed for 38 cycles with the reaction starting at 95°C for 1 min., annealing of 58°C for 15 sec., and extension of 72°C for 30 sec. Amplification products were analyzed on 2% agarose gels with ethidium bromide and documented under UV. The presence of a PCR product of the correct molecular weight indicated the presence of either unmethylated or methylated alleles. In case of appearance of both unmethylated and methylated signals in a gel, gene was considered as being methylated.

RNA extraction, cDNA synthesis and real time quantitative RT-PCR
----------------------------------------------------------------

Samples were collected after surgical resection, snap-frozen and stored in liquid nitrogen until RNA extraction*.*Total RNA from cryogenically homogenized tumor tissue was purified using TRIzol Reagent (Ambion, Life Technologies). To increase the yield of RNA, homogenate was additionally sonicated using ultrasound (500-Watt ultrasonic processor, Cole Parmer). After purification, RNA quality and amount was estimated by NanoDrop system (Thermo Scientific) and stored at -80 °C. RNA integrity was verified by electrophoresis in a 2% agarose gel. RNase-free DNase (ThermoFisher Scientific) was used in order to avoid DNA contamination. Reverse transcription was carried out using RevertAid H Minus M-MuLV Reverse Transcriptase (Thermofisher Scientific) and random hexamer primers (Thermofisher Scientific) in a total reaction volume of 20 µl according to the manufacturer\'s protocol. For inhibition of mRNA degradation RiboLock RNase inhibitor (ThermoFisher Scientific) was used. After synthesis cDNA stock was stored at -80 °C.

*NDRG2* mRNA expression study was performed using quantitative real-time reverse transcriptase PCR SYBR Green I analysis in 3 replicates on 7500 Fast Real-time PCR detection system (Applied Biosystems) and Relative Quantitation method (ΔC~T~). Primer pair 5\'-CATTACACATGCACCCAACC-3\' (sense) and 5\'-GGAGTCAGCCATCTTGAGGA-3\' (antisense) has been used for detection of *NDRG2* gene (amplicon length: 128 bp); primer pair 5\'-AGAGCTACGAGCTGCCTGAC-3\' (sense) and 5\'-AGCACTGTGTTGGCGTA CAG-3\' (antisense) has been used for detection of endogenous control *β-actin* gene (amplicon length: 184 bp) (Metabion International AG). Reactions have been assembled into a total volume of 12 µl of each, which included: 15 ng of the cDNA, 6 μl Maxima Hot Start PCR Master Mix (Thermofisher Scientific) with Hot start Taq DNA polymerase, primers for *NDRG2* and *β-actin* to a total concentration of 0.5 µM and 0.2 µM, respectively, and nuclease-free water. PCR has been carried out for 40 cycles consisting of 95 °C for 30 sec., 60 °C for 30 sec., and 72 °C for 30 sec. Fluorescent data were converted to threshold cycle (C~T~) measurements. C~T~ values from three replicates were averaged for both the target (*NDRG2*) and control (*β-actin*) genes, and ΔC~T~values were calculated according to the formula *ΔC~T~ = C~T~ NDRG2 - C~T~ β-actin*. The final result was given as 2^-(ΔCT)^calculation. Human normal brain RNA sample "FirstChoice Human Brain Reference RNA" (Ambion), which was a pool of RNAs assembled from multiple donors from several brain regions, as described by the manufacturer, served as a control sample for standard curve design. Standard curve parameters were as follows: for *NDRG2*: efficiency 105.7 %, R^2^ 0.99, slope -3.33; for *β-actin*: efficiency 101.2 %, R^2^0.997, slope -3.29, thereby confirming the suitability of PCR conditions and primers for mRNA quantitation.

Whole-tissue extract preparation and Western blot analysis
----------------------------------------------------------

Whole-tissue extracts of the tumor samples have been routinely prepared by resuspending the sample (100-200 µg) in RIPA lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Igepal CA-630 (Sigma-Aldrich), 0.5% sodium deoxycolate, 0.1% SDS) supplemented with a protease inhibitor cocktail (Sigma-Aldrich) and homogenizing using an ultrasonic sonifier (500-Watt Ultrasonic Processor, Cole-Parmer). Subsequently, the extracts were cleared by centrifugation for 30 min at 13.000×g at 4 °C. 80 μg of the total extract protein were fractionated by 7.5% SDS-PAGE and transferred to nitrocellulose membranes. Immobilized proteins were incubated for 2 h at 25 °C with the primary rabbit antibody against NDRG2 (Nordic BioSite, catalog No. 12015-1-AP (antigen peptide region 1-357 a.a.), dilution 1:500) in blocking solution (5% nonfat milk in phosphate-buffered saline (PBS)). After extensive washing in PBS-T buffer (PBS supplemented with 0.5% Tween-20), membranes were incubated with the horseradish peroxidase- (HRP-) conjugated anti-rabbit secondary antibody (Life Technologies, catalog No. 656120, dilution 1:2000) for 1 h at 25 °C. For detection of beta-actin on the same membranes, the membranes were first cleared of the NDRG2 antibody complexes by washing in the mild-striping buffer (25mM glycine, 2% SDS, pH 2.0) and reprobed with the primary monoclonal mouse antibody against beta-actin (Antibodies-Online, catalog No. ABIN559692, dilution 1:2000) for 1 h at 25 °C followed by incubation with the HRP-conjugated anti-mouse secondary antibody (Life Technologies, catalog No. 626520, dilution 1:2000) for 1 h at 25 °C. Immunocomplexes were visualized using enhanced chemiluminescence reagents (Life Technologies) and documented by using gel imaging system GelDoc-It2 (Analytika Jena AG). Values of NDRG2 and beta-actin signals were calculated by using image analysis program ImageJ (National Institutes of Health, U.S.A.).

In the experimental setup, the set of 88 glioma tumor samples was organized in 6 groups each of which containing of 16-17 tissue extracts prepared from tumors of different malignancy grade (groups 1-4 contained samples of grades I-IV, whereas groups 5 and 6 contained only grades II-IV due to the scarcity of the grade I and grade III material). NDRG2 protein levels of each of the tested glioma sample were estimated by performing a densitometric analysis of the digital chemiluminiscence signals of immunoblots (Figure [3](#F3){ref-type="fig"}C). A separate immunoblot analysis was performed on a group of samples containing arbitrarily chosen representative samples from each of the 6 sample groups. NDRG2 signals obtained from these group representatives were used to normalize NDRG2 values (in addition to the normalization with the beta-actin values) obtained from all 6 sample groups. Subsequently, the normalized NDRG2 signal value of each tumor sample was divided by the average signal value calculated from the total of 89 samples resulting to the final value of the relative NDRG2 protein expression.

Statistical analyses
--------------------

For real-time PCR and Western-blot assays, differences across groups were analyzed using Kruskal-Wallis test (comparison of \>2 groups). For MSP data analysis, chi-square test was used to evaluate methylation frequency differences between tumor grades. To evaluate expression differences across gene methylation groups, Mann-Whitney test was used (comparison of 2 groups). Correlation between gene expression at mRNA and protein level was calculated using Spearman correlation coefficient. The association among various factors, such as *NDRG2* promoter methylation, mRNA and protein expression level, and clinical parameters (age, gender, tumor grade, survival groups) were analyzed with the chi-square test.

For the analysis of the prognosis of the patients, survival was calculated from the date of operation until death, or the date of the last follow-up. Survival was analyzed with the Kaplan-Meier method, and the log-rank test was used to compare difference of survival curve between groups. To show the reliability of the survival estimate, the confidence interval (CI) with 95% confidence level was presented. Prognostic factors such as gender, age and clinical grade were first examined individually (univariate analysis), and all factors that had strong impact on survival were then evaluated jointly in Cox regression analysis (multivariate analysis).

Data analysis was performed using the SPSS for Windows (version 21.0, IBM) and p\<0.05 was considered significant.

Results
=======

NDRG2 promoter methylation frequency in glioma is grade-dependent
-----------------------------------------------------------------

*NDRG2* promoter methylation status has been determined in 137 samples of different grade gliomas by using methylation-specific PCR (Figure [1](#F1){ref-type="fig"}C). As shown in Figure [1](#F1){ref-type="fig"}A and Table [1](#T1){ref-type="table"}, moderate *NDRG2* promoter methylation frequencies have been determined in grade I, II and III astrocytomas with the slight variation in methylation percentage values between these grades: 14.3% (2 out of 14), 17.8% (8 out of 45), and 20.7% (6 out of 29), respectively. In contrast, methylation frequency of *NDRG2* promoter was markedly increased to the value of 49.0% (24 out of 49) in glioblastoma tumors (Chi-square test, p\>0.05). It should be noted, that *NDRG2* methylation signal in control normal brain tissue was absent (Figure [1](#F1){ref-type="fig"}C). These results indicate that promoter methylation of *NDRG2* is tumor-specific and is associated with the aggressiveness of glioma tumor.

NDRG2 expression is reduced in glioblastoma
-------------------------------------------

Since our DNA methylation experiments demonstrated a grade-dependent increase in *NDRG2* promoter methylation frequency in gliomas, in our next series of experiments, we asked whether the methylation status of the *NDRG2* promoter reflects on expression levels of this gene. First, we decided to analyze *NDRG2* mRNA levels by using real-time PCR (RT-PCR) technique on mRNA isolated from glioma tumor samples of the same set that has been used for DNA methylation studies. *NDRG2* mRNA values determined in 112 gliomas (10 astrocytomas grade I, 39 astrocytomas grade II, 20 astrocytomas grade III and 43 glioblastomas) were normalized to the values of *β-actin* mRNA, which has been used as an internal control. As shown in Figure [2](#F2){ref-type="fig"}A, median mRNA *NDRG2* expression levels were dramatically reduced in glioblastoma samples to about 10-fold compared to grade I-III gliomas (Kruskal-Wallis test, p\<0.0001). Pairwise comparisons of grade I, II and III gliomas using the Kruskal-Wallis test (p\>0.05) did not reveal significant differences in *NDRG2* mRNA median values in those grades.

To investigate whether the reduced *NDRG2* expression levels detected at mRNA level in highly malignant glioblastomas were associated with reduced NDRG2 protein expression, we decided to perform Western blot analysis on 88 glioma tumors (12 astrocytomas grade I, 31 astrocytomas grade II, 18 astrocytomas grade III and 27 glioblastomas) by using a NDRG2-specific antibody (Figure [3](#F3){ref-type="fig"}C, please see \"Materials and Methods\" for details about the experimental setup). Consistent with the mRNA data, NDRG2 protein level was markedly reduced in glioblastomas (to about 3- to 4-fold) as compared to grade I, II and III gliomas (Kruskal-Wallis test, p\<0.0001, Figure [3](#F3){ref-type="fig"}A). Similarly to what has been observed for mRNA levels of *NDRG2*, differences in NDRG2 protein expression were not significant between grade I, II and III gliomas according to the Kruskal-Wallis test (p\>0.05). As a noteworthy observation, the value of the relative NDRG2 protein expression obtained from normal cortex sample (1.6) was closer to the median expression values of grade I, II and III gliomas (1.1, 1.1, and 1.2, respectively) compared to the significantly lower median value of glioblastomas (0.3).

Next, we analyzed the relationship between *NDRG2* transcript levels and NDRG2 protein levels in 77 glioma samples (9 astrocytomas grade I, 29 astrocytomas grade II, 13 astrocytomas grade III and 26 glioblastomas). For this purpose, *NDRG2* mRNA expression values were categorized into three expression groups ("low", "medium" and "high") compared to the mean value of NDRG2 expression in normal brain tissue: expression values 1.5-fold lower (≤-1.5) compared to the mRNA levels in normal brain were referred to as "low" *NDRG2* expression, expression values 1.5-fold higher (\>1.5) compared to normal brain were referred to as "high" expression, and values ranging in between (from -1.5 to 1.5) were referred to as "medium" expression. This mRNA expression level classification refers to the log2 scale used in Figure [2](#F2){ref-type="fig"}. The comparison of NDRG2 protein expression levels in tumors of "low" (n=23), "medium" (n=42) and "high" (n=12) mRNA expression groups demonstrated a significant correlation of *NDRG2* transcript level with the NDRG2 protein expression level (Spearman correlation 0.653, p\<0.0001, Figure [2](#F2){ref-type="fig"}C). Taken together, our data shows that: 1) *NDRG2* expression is significantly downregulated in glioblastomas at both mRNA and protein levels and 2) expression of this gene is negatively associated with tumor progression.

Correlation analysis of NDRG2 gene promoter methylation, mRNA and protein expression in gliomas
-----------------------------------------------------------------------------------------------

To investigate whether methylation of *NDRG2* promoter accounted for the reduced expression of this gene in gliomas, we compared *NDRG2* mRNA level values (obtained from RT-PCR experiment) in glioma tumors with methylated *NDRG2* promoter with those of which *NDRG2* promoter was unmethylated within each malignancy group (Figure [2](#F2){ref-type="fig"}B). The analysis showed no significant differences in *NDRG2* transcript levels when tumors with methylated *NDRG2* compared with tumors with unmethylated *NDRG2* in all four glioma malignancy grades (Mann-Whitney test, p\>0.05). In addition, the comparison of *NDRG2* mRNA levels between the group of *NDRG2* methylation samples (a total of 35 tumors) and the group of tumors with umethylated NDRG2 (a total of 77) also revealed no significant differences (Chi-square test, p\>0.05, Table [1](#T1){ref-type="table"}).

Next, we analyzed NDRG2 protein level correlation with gene methylation. For this purpose, NDRG2 protein expression data values have been divided into three categories: values that were lower than 0.75 compared to the total average value (i.e., average immunoblot signal deduced from all tested protein samples, please see "Materials and Methods" for details) were ranked as "low" NDRG2 protein expression, values ranging between 0.75 and 1.5 were considered as "medium" NDRG2 expression, and values that exceeded 1.5 were ranked as "high" NDRG2 expression. In line with mRNA observations, a statistical analysis of the Western blot data showed that the NDRG2 protein expression levels within the group of total 26 tumors with methylated *NDRG2* promoter do not differ significantly from the group of total 62 tumors with unmethylated *NDRG2* (Chi-square test, p\>0.05, Table [1](#T1){ref-type="table"}). These findings suggest that *NDRG2* gene promoter methylation does not represent as being the major mechanism of gene silencing in gliomas.

Survival analyses
-----------------

Next, we assessed how changes in *NDRG2* promoter methylation and *NDRG2* expression reflect on the outcome of glioma patient by using a log-rank test. The follow-up clinical data was available for all of the patients the tumor samples of whom have been analyzed in our study. 81 patients out of 138 had died of their tumors, while 57 patients at the closure of the study were still alive and were censored during the survival analysis. We detected significant differences in survival time between sets of gliomas stratified by *NDRG2* methylation status (Log-rank test, χ^2^=5.99, df=1, p=0.014; Figure [1](#F1){ref-type="fig"}B). The cumulative 2-year survival rate in unmethylated group was about 65% compared to 42% of surviving patients in methylated group. Median survival time in unmethylated *NDRG2* group was 56 months (95% Confidence interval, CI, 29.9-82.3 months), whereas in methylated *NDRG2* group the length of survival time was reduced to 20 months (95% CI, 9.0-30.9 months).

Experimental values of relative mRNA and protein expression of *NDRG2* categorized into "low", "medium" and "high" expression groups (described above) were used for survival analysis. We found that the "low" expression level of *NDRG2* was significantly associated with the less favorable survival rate compared to the "high" expression group in both mRNA (Log-rank test, χ^2^=31.08, df=2, p=0.0001; Figure [2](#F2){ref-type="fig"}D) and protein analyses (Log-rank test, χ^2^=13.4, df=2, p=0.001; Figure [3](#F3){ref-type="fig"}B). Median survival time in "low" expression group was 10.5 months (95% CI, 7.3-13.8 months) and 17.2 months (95% CI, 0-34.9 months) in mRNA and protein analysis, respectively. Survival time in patients having tumors expressing "medium" mRNA and protein level was 56.8 months (95% CI, 40.8-72.7 months) and 56.1 months (95% CI, 36.5-75.7 months), respectively. Median survival time in "high" mRNA and protein expression groups could not be determined because more than 50% of patients in those groups were alive at the time of the analysis and survived longer than the overall median level of each group.

Cox univariate regression analysis showed patient age (p=0.0001), glioma pathological grade (p=0.0001), *NDRG2* promoter methylation (p=0.016), mRNA transcript level (p=0.0001) and protein expression (p=0.001) as independent variables associated with patient survival (data not shown). These analyses suggest that astrocytoma progression from low to high grade is correlated with *NDRG2* gene promoter methylation and reduced mRNA and protein expression in tumor. However, results from multivariate Cox analysis did not confirm this when the *NDRG2* methylation status, mRNA level and protein expression level were considered as independent prognostic factors (p\>0.05). Thus, future studies with larger sample sizes should be completed to confirm this trend.

Relationship between NDRG2 promoter methylation, mRNA and protein expression and clinical characteristics of glioma patients
----------------------------------------------------------------------------------------------------------------------------

Clinicopathological significance of *NDRG2* gene methylation and downregulation of *NDRG2* expression in gliomas was evaluated by correlating methylation and expression patterns of *NDRG2* with clinical parameters of the patient (Table [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). We found positive significant relationship between *NDRG2* gene promoter methylation and older patient age, higher tumor malignancy and shorter survival time (Chi-square test, p\<0.05, Table [1](#T1){ref-type="table"}). Patients older than 50 years 1.6 times more frequently had tumors with methylated *NDRG2* promoter as compared to the younger patients. Nearly half (49%) of glioblastoma patients had tumors with methylated *NDRG2*, whereas in grade I-III astrocytomas *NDRG2* methylation was found in about one-fifth (17%) of tumors. When patients were categorized in two groups according survival time (\<24 months and ≥24 months), analysis showed that tumors with methylated *NDRG2* promoter were present in 41% of patients surviving less than 2 years after diagnosis. *NDRG2* gene promoter methylation did not significantly correlate with patient gender and, as it has already been noted above, *NDRG2* mRNA and protein expression values (Chi-square test, p\>0.05, Table [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}).

We found negative significant relationships between NDRG2 protein expression and older age of the patient, higher tumor malignancy grade and shorter patient survival (Chi-square test, p\<0.05, Table [2](#T2){ref-type="table"}). Noteworthy, more than 70% of patients older than 50 years had glioma tumors with "low" NDRG2 protein expression, whereas younger patients more often had tumors with NDRG2 expression levels referred to as "medium" and "high". In glioma grade groups 88.9% of glioblastomas had "low" protein expression pattern as compared to 25-40% of tumors in grade I-III malignancy groups with "low" NDRG2 expression. Correlation analysis with the survival time showed that 73.3 % of patients surviving less than 2 years after diagnosis had tumors with "low" NDRG2 protein expression (Chi-square test, p\<0.05). However, no significant correlation was found between NDRG2 protein expression and patient gender (Chi-square test, p\>0.05). These results confirm that *NDRG2* epigenetic alterations and downregulation of expression are associated with the aggressive behavior of glioma in terms of tumor spread and poor patient survival.

Discussion
==========

In the current study, we used a complex approach to define NDRG2 activity at DNA, RNA and protein levels and its involvement in glioma tumorigenesis. We began our study by defining *NDRG2* promoter methylation status in different grade glioma samples. We have determined 14-20% *NDRG2* methylation frequency in grade I-III gliomas, whereas methylation markedly increased to 49 % in grade IV glioblastomas (Figure [1](#F1){ref-type="fig"}A). In addtion to studies in glioblastoma, a number of studies using various techniques have shown frequent *NDRG2* promoter methylation in different cancer cell lines and tumor tissues such as anaplastic meningiomas (20%), liver cancer (77%), colon cancer (27%), oral squamous cell carcinoma (62%), colorectal (64%) and gastric cancer (54%) [@B4], [@B13], [@B24]-[@B27]. *NDRG2* promoter methylation was observed to be associated with higher malignancy grade in meningiomas, colon cancer, gastric cancer and, in agreement with our findings, in glioma tumors [@B4], [@B5], [@B24], [@B27]. The current study showed significant positive correlation between *NDRG2* methylation and patient age in gliomas. Moreover, correlation analysis revealed that higher frequency of gene methylation was more often observed in higher malignancy grade tumors and that methylation was more frequently associated with shorter survival time (Table [1](#T1){ref-type="table"}). Further survival analysis in this study, in which we included tumors of different malignancy grade, demonstrated significant correlation between *NDRG2* promoter methylation and poor patient outcome (Figure [1](#F1){ref-type="fig"}B). This is in contrast to earlier findings [@B5], [@B22], where studies on *NDRG2* promoter methylation and patient survival have been done with the focus on glioblastoma alone.

Along with the changes in promoter methylation frequency, we also observed a marked decrease in *NDRG2* expression at mRNA level in glioblastomas as compared to normal brain and grade I-III gliomas. Similarly, *NDRG2* expression at protein level was observed to be highly downregulated in glioblastomas as compared to grade I-III gliomas. NDRG2 protein expression profiles strongly correlated with those of mRNA (Figure [2](#F2){ref-type="fig"}C). It should be noted, however, that sharp decrease in NDRG2 protein expression, in addition to glioblastoma samples, has also been observed in individual samples of grade I-III gliomas. Several studies have shown low or undetectable *NDRG2* expression in a number of human cancers including liver cancer, colon cancer, hepatocellular carcinoma, breast cancer, and squamous cell carcinoma [@B13], [@B16], [@B24], [@B28], [@B29]. Kaplan-Meier analysis indicated poor outcome for patients with reduced *NDRG2* expression at both mRNA and protein level (Figures [2](#F2){ref-type="fig"}D and [3](#F3){ref-type="fig"}B, respectively), suggesting that gene downregulation have clinical importance in gliomas. In line with our observations, other studies by using immunohistochemical method have shown a negative correlation between *NDRG2* expression level and glioma grade, and positive correlation with patient survival time [@B6], [@B7]. Taken together, our results support the evidence provided by other laboratories that *NDRG2* expression is frequently reduced in clinically aggressive types of gliomas and that the gene is involved in gliomagenesis.

Molecular mechanisms underlying the downregulation of *NDRG2* are yet to be elucidated. Several studies suggested the promoter methylation being the major cause of the loss of *NDRG2* expression in meningioma, hepatocellular carcinoma, colon cancer, oral squamous cell carcinoma, colorectal cancer, as well as in glioma [@B4], [@B5], [@B13], [@B24]-[@B26]. In contrast to the earlier observations, our study have not found relationship between *NDRG2* gene promoter methylation and expression of this gene at both mRNA level (Figure [2](#F2){ref-type="fig"}B) and protein level (correlation analysis not shown) in gliomas stratified by grades. Moreover, correlation analysis between gene methylation, mRNA and protein expression showed no association in the whole glioma sample as well (Table [1](#T1){ref-type="table"} and Table [2](#T2){ref-type="table"}). Among possible explanations of the discrepancy between *NDRG2* methylation and expression data could be intratumoral heterogeneous methylation pattern and normal cells (normal tissue and infiltrating white blood cells) contaminating tumor tissue. The discussed discrepancies do not exclude the possibility that *NDRG2* promoter may be subjected to epigenetic silencing through DNA methylation, however, our data suggest that additional mechanisms of regulation could be responsible for differential expression of *NDRG2*. For example, it has been reported that DNA alterations, such as mutations and genomic deletions, may deregulate gene expression in breast cancer cell lines [@B30]. Loss of chromosome 14q, where the *NDRG2* gene is located, is a common feature in different tumor types including astrocytic tumors [@B31]. An alternative regulatory mechanism for *NDRG2* expression has been demonstrated in the study by Feng et al. [@B26], where it has been shown that *NDRG2* expression in colon cancer was downregulated by microRNAs, whereas Yamamura et al. [@B32] found that histone modification by deacetylation in pancreatic cancer cell lines is yet another mechanism for downregulating *NDRG2*. Therefore, given the plethora of different mechanisms, of regulation of *NDRG2* expression, including DNA methylation, future studies should clarify which of these possible mechanisms, if any in particular, could be delineated as major determinants of *NDRG2* activity.

In conclusion, our findings highlight the usefulness of combining epigenetic data to gene expression patterns at mRNA and protein level in tumor biomarker studies, and suggest that *NDRG2* downregulation might bear influence on glioma tumor progression while being associated with higher malignancy grade.
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*NDRG2*

:   N-myc downstream regulated gene 2

WHO

:   World Health Organization

MSP

:   methylation-specific PCR

CI

:   confidence interval.

![Analysis of *NDRG2* methylation in different grade gliomas and effects of *NDRG2*methylation on patient survival. (A) Methylation frequency (%) shown in the bar plot; asterisk indicates significant differences between glioma grades (p\<0.05). (B) Kaplan-Meier survival curves for survival (months) of all glioma patients stratified by *NDRG2* methylation status; Log-rank test, χ^2^=5.99, df=1, p=0.014. (C) Representative MS-PCR for *NDRG2* in different grade glioma tumor specimens. *U* represents amplification of unmethylated alleles, and *M* represents methylated alleles. Standard Bisulfite Converted Universal Methylated Human DNA (*M contr.*) and normal human peripheral lymphocytes (*U contr.*) served as positive and negative methylation controls, respectively. *H~2~O* - water control, *GBM* - glioblastoma (astrocytoma of WHO grade IV), *AI*, *AII*, and *AIII* designate astrocytomas of WHO grade I, II, and III, respectively.](jcav05p0446g001){#F1}

![Relative *NDRG2* mRNA expression in different grade gliomas. (A) Real-time qRT-PCR was used to determine relative *NDRG2* mRNA levels in gliomas while using *β-actin* as an internal control for normalization. Data are expressed as log2 of fold change in *NDRG2* mRNA expression compared to the normal brain control (indicated by an unfilled diamond). Horizontal lines mark median expression. Relative mRNA expression was highly downregulated in glioblastomas (GBM) as compared to I, II and III grade astrocytomas (\*\*p\<0.01, \*\*\*p\<0.001). (B) Box plots of relative *NDRG2* mRNA expression in different grade glioma sample groups, each stratified by methylation statuses of *NDRG2* promoter. The line inside each box represents the median, and the lower and upper edges of the boxes represent the 25th and 75th percentiles, respectively, and upper and lower lines outside the boxes represent minimum and maximum values (error bars). Cross-hatched boxes represent samples with methylated *NDRG2*(marked as *M*), whereas unfilled boxes represent samples with unmethylated *NDRG2*(marked as *U*). (C) The box plot demonstrates relative NDRG2 protein expression in 77 glioma samples stratified by low, medium and high mRNA expression groups. Significant (\*\*\*p\<0.001) correlation was observed between *NDRG2* mRNA and protein expression. The plot markings are the same as those in panel *B*. (D) Kaplan-Meier survival curves representing the overall survival of the whole set of glioma samples (n=112) stratified by mRNA expression levels (low, medium, high); Log-rank test, χ^2^=31.08, df=2, p=0.0001.](jcav05p0446g002){#F2}

![NDRG2 protein expression analysis. (A) NDRG2 protein expression levels in glioma grades I, II, III and IV (GBM). Protein expression was highly downregulated in glioblastomas (GBM) as compared to lower grade (I, II, III) astrocytomas (\*\*\*p\<0.001). (B) Kaplan-Meier survival curves for survival of all glioma patients (n=88) stratified by protein expression (low, medium, high); Log-rank test, χ^2^=13.4, df=2, p=0.001. (C) Representative Western blot result of NDRG2 protein expression in glioma in one of the sample groups. Methylation status in samples is indicated as (+) methylated, and (-) unmethylated. Positions of two isoforms [@B33] of NDRG2, β-actin (*Actin*), kDa values of the protein size marker, and possible degradation products of NDRG2 (*asterisks*) are indicated.](jcav05p0446g003){#F3}

###### 

Relationship between *NDRG2* promoter methylation, patient clinical characteristics, mRNA and protein expression level.

                                      Number of patients   *NDRG2* methylation   p-value     
  -------------------------- -------- -------------------- --------------------- ----------- -------
  Cases                               137                  39 (28.5)             98 (71.5)   
  Sex                        Male     62                   16 (25.8)             46 (74.2)   0.346
                             Female   75                   24 (32.0)             51 (68.0)   
  Age (years)                ≤50      73                   15 (20.5)             58 (79.5)   0.037
                             \>50     64                   24 (37.5)             40 (62.5)   
  Grade                      I        14                   2 (14.3)              12 (85.7)   0.001
                             II       45                   8 (17.8)              37 (82.2)   
                             III      29                   5 (17.2)              24 (82.8)   
                             GBM      49                   24 (49.0)             25 (51.0)   
  Survival (months)          \<24     56                   23 (41.1)             33 (58.9)   0.008
                             ≥24      81                   16 (19.8)             65 (80.2)   
  *NDRG2* mRNA expression    Low      40                   15 (37.5)             25 (62.5)   0.555
                             Medium   49                   14 (28.6)             35 (71.4)   
                             High     23                   6 (26.1)              17 (73.9)   
  NDRG2 protein expression   Low      42                   11 (26.2)             31 (73.8)   0.472
                             Medium   29                   11 (37.9)             18 (62.1)   
                             High     17                   4 (23.5)              13 (76.5)   

^a^M - methylated; ^b^U - unmethylated

###### 

Relationship between NDRG2 protein expression and patient clinical characteristics, *NDRG2* methylation and mRNA expression level.

                                     Number of patients   Protein expression   p-value                 
  ------------------------- -------- -------------------- -------------------- ----------- ----------- --------
  Cases                              88                   42 (47.7)            29 (33.0)   17 (19.3)   
  Sex                       Male     40                   20 (50.0)            12 (30.3)   8 (20.0)    0.864
                            Female   48                   22 (45.8)            17 (35.4)   9 (18.8)    
  Age (years)               ≤50      49                   14 (28.6)            23 (46.9)   12 (24.5)   0.0001
                            \>50     39                   28 (71.8)            6 (15.4)    5 (12.8)    
  Grade                     I        12                   5 (41.7)             4 (33.3)    3 (25.0)    0.0001
                            II       31                   8 (25.8)             12 (38.7)   11 (35.5)   
                            III      18                   5 (27.8)             10 (55.6)   3 (16.7)    
                            GBM      27                   24 (88.9)            3 (11.1)    0           
  Survival (months)         \<24     30                   22 (73.3)            7 (23.3)    1 (3.3)     0.001
                            ≥24      58                   20 (34.5)            22 (37.9)   16 (27.6)   
  *NDRG2* methylation       ^a^M     26                   11 (42.3)            11 (42.3)   4 (15.4)    0.472
                            ^b^U     62                   31 (50.0)            18 (29.0)   13 (21.0)   
  *NDRG2* mRNA expression   Low      23                   20 (87.0)            2 (8.7)     1 (4.3)     0.0001
                            Medium   42                   17 (40.5)            18 (42.8)   7 (16.7)    
                            High     12                   2 (16.7)             3 (25.0)    7 (58.3)    

^a^M - methylated; ^b^U - unmethylated}
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